LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Kidney Yang Deficiency Syndrome Exacerbates Aβ

    Jiang, Xia / Chen, Lin / Fu, Qing / Ma, Dan Li / Liu, Xue Ting / Wang, Xiao Yi

    Current Alzheimer research

    2023  Volume 20, Issue 1, Page(s) 48–58

    Abstract: Background: Traditional Chinese medicine (TCM) indicates that Alzheimer's disease (AD) is considered the consequence produced by Kidney Yang Deficiency Syndrome (KDS-Yang), which has similar clinical characteristics to glucocorticoid withdrawal syndrome. ...

    Abstract Background: Traditional Chinese medicine (TCM) indicates that Alzheimer's disease (AD) is considered the consequence produced by Kidney Yang Deficiency Syndrome (KDS-Yang), which has similar clinical characteristics to glucocorticoid withdrawal syndrome. Ginsenoside Re (G-Re) has been found to ameliorate the symptoms and pathological impairments of AD. However, it's not clear whether G-Re could protect memory and synapse lesions against kidney deficiency dementia.
    Methods: Subcutaneous injection of hydrocortisone for 14 days was used to produce KDS-Yang. On the 15th day, Aβ
    Results: Hyperphosphorylation of tau in Aβ
    Conclusion: KDS-Yang might exacerbate AD pathological lesions. Importantly, G-Re is a potential ingredient for protecting against memory and synapse deficits in kidney deficiency dementia.
    MeSH term(s) Rats ; Animals ; Amyloid beta-Peptides/toxicity ; Yang Deficiency ; Alzheimer Disease/metabolism ; Disks Large Homolog 4 Protein ; Kidney/metabolism ; Kidney/pathology ; Synapses/metabolism ; Disease Models, Animal ; Peptide Fragments/toxicity
    Chemical Substances Amyloid beta-Peptides ; ginsenoside Re (46F3R0BL3I) ; Disks Large Homolog 4 Protein ; Peptide Fragments
    Language English
    Publishing date 2023-05-12
    Publishing country United Arab Emirates
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2205170-3
    ISSN 1875-5828 ; 1567-2050
    ISSN (online) 1875-5828
    ISSN 1567-2050
    DOI 10.2174/1567205020666230512094230
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6235: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.

    Li, Xiao-He / Huang, Rui / Yang, Ming / Wang, Jian / Gao, Ying-Hui / Jin, Qian / Ma, Dan-Li / Wei, Lai / Rao, Hui-Ying

    World journal of gastroenterology

    2022  Volume 28, Issue 20, Page(s) 2214–2226

    Abstract: Background: Direct acting antiviral (DAA) therapy has enabled hepatitis C virus infection to become curable, while histological changes remain uncontained. Few valid non-invasive methods can be confirmed for use in surveillance. Gadolinium-ethoxybenzyl- ... ...

    Abstract Background: Direct acting antiviral (DAA) therapy has enabled hepatitis C virus infection to become curable, while histological changes remain uncontained. Few valid non-invasive methods can be confirmed for use in surveillance. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid (Gd-EOB-DTPA) is a liver-specific magnetic resonance imaging (MRI) contrast, related to liver function in the hepatobiliary phase (HBP). Whether Gd-EOB-DTPA-enhanced MRI can be used in the diagnosis and follow up of hepatic fibrosis in patients with chronic hepatitis C (CHC) has not been investigated.
    Aim: To investigate the diagnostic and follow-up values of Gd-EOB-DTPA-enhanced MRI for hepatic histology in patients with CHC.
    Methods: Patients with CHC were invited to undergo Gd-EOB-DTPA-enhanced MRI and liver biopsy before treatment, and those with paired qualified MRI and liver biopsy specimens were included. Transient elastography (TE) and blood tests were also arranged. Patients treated with DAAs who achieved 24-wk sustained virological response (SVR) underwent Gd-EOB-DTPA-enhanced MRI and liver biopsy again. The signal intensity (SI) of the liver and muscle were measured in the unenhanced phase (UEP) (SI
    Results: Thirty-nine patients with CHC were enrolled [average age, 42.3 ± 14.4 years; 20/39 (51.3%) male]. Twenty-one enrolled patients had eligible paired Gd-EOB-DTPA-enhanced MRI and liver tissues after achieving SVR. The mHAI median significantly decreased after SVR [baseline 6.0 (4.5-13.5)
    Conclusion: Gd-EOB-DTPA-enhanced MRI has good diagnostic value for staging fibrosis in patients with CHC. It can be used for fibrotic-change monitoring post SVR in patients with CHC treated with DAAs.
    MeSH term(s) Acetic Acid ; Adult ; Antiviral Agents/therapeutic use ; Biomarkers ; Contrast Media ; Female ; Gadolinium/therapeutic use ; Gadolinium DTPA ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/diagnostic imaging ; Hepatitis C, Chronic/drug therapy ; Humans ; Liver/diagnostic imaging ; Liver/pathology ; Liver Cirrhosis/diagnostic imaging ; Liver Cirrhosis/drug therapy ; Magnetic Resonance Imaging/methods ; Male ; Middle Aged ; Polyamines ; Retrospective Studies ; Rubiaceae
    Chemical Substances Antiviral Agents ; Biomarkers ; Contrast Media ; Polyamines ; diethylenetriamine (03K6SX4V2J) ; Gadolinium (AU0V1LM3JT) ; Gadolinium DTPA (K2I13DR72L) ; Acetic Acid (Q40Q9N063P)
    Language English
    Publishing date 2022-06-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2185929-2
    ISSN 2219-2840 ; 1007-9327
    ISSN (online) 2219-2840
    ISSN 1007-9327
    DOI 10.3748/wjg.v28.i20.2214
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6039: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.

    Huang, Rui / Rao, Hui-Ying / Yang, Ming / Gao, Ying-Hui / Wang, Jian / Jin, Qian / Ma, Dan-Li / Wei, Lai

    World journal of gastroenterology

    2021  Volume 27, Issue 5, Page(s) 404–415

    Abstract: Background: Histological changes after direct-acting antivirals (DAAs) therapy in hepatitis C virus (HCV) patients has not been elucidated. Whether the predominantly progressive, indeterminate and predominately regressive (P-I-R) score, evaluating ... ...

    Abstract Background: Histological changes after direct-acting antivirals (DAAs) therapy in hepatitis C virus (HCV) patients has not been elucidated. Whether the predominantly progressive, indeterminate and predominately regressive (P-I-R) score, evaluating fibrosis activity in hepatitis B virus patients has predictive value in HCV patients has not been investigated.
    Aim: To identify histological changes after DAAs therapy and to evaluate the predictive value of the P-I-R score in HCV patients.
    Methods: Chronic HCV patients with paired liver biopsy specimens before and after DAAs treatment were included. Sustained virologic response (SVR) was defined as an undetectable serum HCV RNA level at 24 wk after treatment cessation. The Ishak system and P-I-R score were assessed. Inflammation improvement and fibrosis regression were defined as a ≥ 2-points decrease in the histology activity index (HAI) score and a ≥ 1-point decrease in the Ishak fibrosis score, respectively. Fibrosis progression was defined as a ≥ 1-point increase in the Ishak fibrosis score. Histologic improvement was defined as a ≥ 2-points decrease in the HAI score without worsening of the Ishak fibrosis score after DAAs therapy. The P-I-R score was also assessed. "absolutely reversing or advancing" was defined as the same directionality implied by both change in the Ishak score and posttreatment P-I-R score; and "probably reversing or advancing" was defined as only one parameter showing directionality.
    Results: Thirty-eight chronic HCV patients with paired liver biopsy specimens before and after DAAs treatment were included. The mean age of these patients was 40.9 ± 14.6 years and there were 53% (20/38) males. Thirty-four percent (13/38) of patients were cirrhotic. Eighty-two percent (31/38) of patients achieved inflammation improvement. The median HAI score decreased significantly after SVR (pretreatment 7.0
    Conclusion: Significant improvement of necroinflammation and partial remission of fibrosis in HCV patients occurred shortly after DAAs therapy. The P-I-R score has potential in predicting fibrosis in HCV patients.
    MeSH term(s) Adult ; Antiviral Agents/therapeutic use ; Hepacivirus/genetics ; Hepatitis C/drug therapy ; Hepatitis C, Chronic/diagnosis ; Hepatitis C, Chronic/drug therapy ; Humans ; Liver Cirrhosis/drug therapy ; Male ; Middle Aged
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2021-02-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2185929-2
    ISSN 2219-2840 ; 1007-9327
    ISSN (online) 2219-2840
    ISSN 1007-9327
    DOI 10.3748/wjg.v27.i5.404
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6039: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir.

    Wang, Xiao-Xiao / Luo, Bi-Fen / Jiang, Han-Ji / Cong, Xu / Jin, Qian / Ma, Dan-Li / Wei, Lai / Feng, Bo

    World journal of gastroenterology

    2018  Volume 24, Issue 40, Page(s) 4554–4564

    Abstract: Aim: To investigate how natural killer (NK) cells are affected in the elimination of hepatitis C virus (HCV) by sofosbuvir/ledipasvir, two highly effective direct-acting antivirals (DAAs).: Methods: Thirteen treatment-naïve and treatment-experienced ... ...

    Abstract Aim: To investigate how natural killer (NK) cells are affected in the elimination of hepatitis C virus (HCV) by sofosbuvir/ledipasvir, two highly effective direct-acting antivirals (DAAs).
    Methods: Thirteen treatment-naïve and treatment-experienced chronic hepatitis C (CHC) patients were treated with sofosbuvir/ledipasvir, and NK cells were detected at baseline, weeks 2, 4, 8 and 12 during therapy, and week post of treatment (Pt)-12 and 24 after the end of therapy by multicolor flow cytometry and compared with those from 13 healthy controls.
    Results: All patients achieved sustained virological response. There was a significant decline in CD56
    Conclusion: NK cells of CHC patients can be affected by DAAs, and phenotypes and function of NK cells recover not at early stage but mainly after the end of sofosbuvir/ledipasvir treatment.
    MeSH term(s) Adult ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; Benzimidazoles/adverse effects ; Benzimidazoles/therapeutic use ; Case-Control Studies ; Cohort Studies ; Drug Therapy, Combination/adverse effects ; Drug Therapy, Combination/methods ; Female ; Fluorenes/adverse effects ; Fluorenes/therapeutic use ; Genotype ; Hepacivirus/drug effects ; Hepacivirus/genetics ; Hepacivirus/immunology ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/immunology ; Hepatitis C, Chronic/virology ; Humans ; Immunity, Innate/drug effects ; Killer Cells, Natural/drug effects ; Killer Cells, Natural/immunology ; Male ; Middle Aged ; Sofosbuvir/adverse effects ; Sofosbuvir/therapeutic use ; Sustained Virologic Response
    Chemical Substances Antiviral Agents ; Benzimidazoles ; Fluorenes ; ledipasvir (013TE6E4WV) ; Sofosbuvir (WJ6CA3ZU8B)
    Language English
    Publishing date 2018-09-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2185929-2
    ISSN 2219-2840 ; 1007-9327
    ISSN (online) 2219-2840
    ISSN 1007-9327
    DOI 10.3748/wjg.v24.i40.4554
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6039: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top